Wells Fargo & Company Terns Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 25,081 shares of TERN stock, worth $195,882. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,081

Previous 14,057 78.42%

Holding current value

$195,882

Previous $92,000 84.78%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.54 - $8.2 $50,048 - $90,396	11,024 Added 78.42%	25,081 $170,000
Q1 2024 May 10, 2024	BUY	$4.86 - $8.19 $9,734 - $16,404	2,003 Added 16.62%	14,057 $92,000
Q4 2023 Feb 09, 2024	BUY	$3.37 - $6.86 $8,654 - $17,616	2,568 Added 27.07%	12,054 $78,000
Q3 2023 Nov 13, 2023	SELL	$4.7 - $8.55 $36,786 - $66,920	-7,827 Reduced 45.21%	9,486 $47,000
Q2 2023 Aug 15, 2023	BUY	$7.35 - $13.29 $125,714 - $227,312	17,104 Added 8183.73%	17,313 $151,000
Q1 2023 May 12, 2023	BUY	$7.91 - $12.0 $656 - $996	83 Added 65.87%	209 $2,000
Q4 2022 Feb 13, 2023	BUY	$4.62 - $10.18 $18 - $40	4 Added 3.28%	126 $1,000
Q3 2022 Nov 14, 2022	BUY	$1.87 - $6.42 $130 - $449	70 Added 134.62%	122 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.5 - $3.0 $841 - $1,683	-561 Reduced 91.52%	52 $0
Q1 2022 May 16, 2022	SELL	$2.83 - $6.7 $13,770 - $32,602	-4,866 Reduced 88.81%	613 $2,000
Q4 2021 Feb 14, 2022	BUY	$5.65 - $10.73 $30,871 - $58,628	5,464 Added 36426.67%	5,479 $39,000
Q3 2021 Nov 15, 2021	BUY	$7.22 - $13.46 $108 - $201	15 New	15 $0
Q2 2021 Aug 16, 2021	SELL	$12.26 - $22.0 $33,273 - $59,708	-2,714 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$17.13 - $27.25 $46,490 - $73,956	2,714 New	2,714 $60,000

Others Institutions Holding TERN

# of Institutions

132

Shares Held

63.4M

Call Options Held

413K

Put Options Held

106K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $294M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Terns Pharmaceuticals, Inc. Transaction History